Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03042910 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT03042910 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 38 participants.
The verdict
NCT03042910, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This study is designed to evaluate the effects of talazoparib on cardiac repolarization in patients with advanced solid tumors with no available standard treatment options.
Interventions
- DRUG Talazoparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-10-13 |
| Est. Completion | 2017-06-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03042910
The ClinicalTrials.gov registry entry for NCT03042910 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Talazoparib is the first listed.
NCT03042910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03042910 about?
NCT03042910 is a clinical study titled "A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors". This study is designed to evaluate the effects of talazoparib on cardiac repolarization in patients with advanced solid tumors with no available standard treatment options.
What is the current status of trial NCT03042910?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2016-10-13. Estimated completion is 2017-06-22.
What interventions are being tested in trial NCT03042910?
The interventions under investigation include: Talazoparib (DRUG).
Who is sponsoring clinical trial NCT03042910?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.